Anatara Lifesciences is developing non-antibiotic oral solutions for gastrointestinal diseases in animals and humans. Our lead product Detach™ is a natural product that will help address global concerns around the overuse of antibiotics in animals and their feed that is contributing to the rise of so-called “super bugs” that make infectious diseases harder to treat. The Anatara team has a strong track record in biological science as well as building and growing international biotech companies.
Latest news All news
BRISBANE, 17 October 2014: Gastrointestinal therapeutic company, Anatara Lifesciences (ASX: ANR) is pleased to announce it has completed its first pilot manufacturing runs of DetachTM and will now initiate manufacture required for registration purposes under the Australian Pesticides and Veterinary Medicines Authority’s (AVPMA’s) product registration approval process.Read more »
Anatara Lifesciences has been added to the ASX’s Official List and it’s shares are due to commence trading on Thursday, October 16, 2014.
For more read here.
Anatara Lifescience’s impending listing on the Australian Securities Exchange has been discussed in the Float Watch section of Australia’s only daily broadsheet newspaper The Australian.
Analyst Tim Morris, from wise-owl.com, notes that the global appetite for pork is strong as Anatara develops Detach™, our non-antibiotic treatment for diarrhoea in pigs.
He says Anatara controls intellectual property associated with an earlier formulation of Detach™ and that Anatara has further developed the therapy in preparation for field trials.
Read more here.